A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Aroa Biosurgery Launches Large Format Endoform ®

Used for the Treatment of Larger, More Complex Wounds

February 7, 2020

Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, has now launched a large format version of its Endoform® Natural product.

The largest of Aroa’s wound care products, the 8.5 by 6-inch device has been launched in the United States and Canadian markets, following its recent approval for reimbursement within the U.S. healthcare system.

Aroa Biosurgery Chief Executive, Brian Ward said this large-format version of Endoform® Natural addresses the growing need to treat large wounds with a single sheet of their extracellular matrix-based product and provides more options for clinicians.

“We saw a need to offer Healthcare Providers a simple option for larger and often more difficult-to-treat wounds arising from trauma and complications from surgical wounds, or other diseases where healing is impaired. This format is also suitable for wounds such as chronic wounds and venous leg ulcers.

“We are also seeing that Endoform® Natural is increasingly being used in conjunction with negative pressure wound therapy, and this large-format will be particularly useful in these treatment applications.”

Aroa Biosurgery intends to make the large format available in a range of global markets as and when regulatory approvals are granted.

“Aroa is committed to having solutions for a wide variety of wounds and wound sizes, and to partnering with clinicians to ensure there are effective solutions for patients presenting with an array of challenging wounds,” says Brian Ward.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy